Alaunos Therapeutics Inc (TCRT) Stock AnalysisTCRTAlaunos Therapeutics Inc

Alaunos Therapeutics, Inc. is a biotechnology company. The Company's obesity and metabolic disorders program is advancing ALN1003, an oral small-molecule candidate being evaluated as a potential differentiated, non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology. ALN1003 is a preclinical, non-incretin, oral candidate targeting metabolic dysfunction beyond weight loss that may address insulin resistance, adipose signaling, liver biology, and body composition. ALN1003 is a preclinical, oral, non-hormonal metabolic therapeutic candidate being evaluated for: obesity-related metabolic dysfunction, MASH-relevant biology, and insulin resistance. The Company is advancing a pipeline of potentially transformative therapies for pulmonary hypertension and related cardiopulmonary diseases. The Company is developing ActRII-Fc ligand traps and complementary biologics. The Company's programs include VLR199, VLR247, VLR258, VLR360 and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alaunos Therapeutics Inc is not a good buy right now due to significant losses and declining performance metrics. The current price is $0.7858, which is down 76.04% year-to-date. The company reported a Q2 loss of $952,000, and its forward P/E ratio is 18.48, indicating potential overvaluation given the financial struggles. The main risk is the ongoing negative net income, with a net margin of -106,200% in Q2 2025, which raises concerns about its future viability.